Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback